tetano
Editor, Senior Moderator
Isr Med Assoc J
. 2022 May;24(5):317-319.
Critical Stepwise Decline of Antibodies against SARS-CoV-2 among Chronic Hemodialysis Patients 180 Days Post Comirnaty Vaccine
Nomy Levin-Iaina[SUP] 1 2 [/SUP], Avital Angel-Korman[SUP] 3 1 [/SUP], Adi Leiba[SUP] 3 1 4 [/SUP], Esther Peres[SUP] 3 [/SUP], Gabriel Bryk[SUP] 5 [/SUP], Vladimir Rapoport[SUP] 3 [/SUP], Zeev Katzir[SUP] 3 1 [/SUP], Yoram Yagil[SUP] 1 4 2 [/SUP], Tal Brosh-Nissimov[SUP] 6 1 [/SUP]
Affiliations
Abstract
Background: The reduced immune response of maintenance hemodialysis patients to coronavirus disease 2019 (COVID-19) vaccines is a major concern.
Objectives: To analyze the late (6 months after full vaccination) antibody response and compare it to early post-vaccination titer.
Methods: We conducted a multicenter prospective study of 13 hemodialysis units in Israel.
Results: We demonstrated that the low titers observed among ESRD patients 2-3 months after vaccination with the Comirnaty vaccine (median 63.8 AU/ml) declined to critically lower values 6 months after full vaccination. (Mediananti S antibodies, 31 AU/ml). Seropositivity significantly declined among hemodialysis patients from 89% to 74% (P < 0.0001), although it did not significantly change among controls.
Conclusions: We recommend all patients on hemodialysis receive a booster COVID-19 vaccine 6 months after the second dose.
. 2022 May;24(5):317-319.
Critical Stepwise Decline of Antibodies against SARS-CoV-2 among Chronic Hemodialysis Patients 180 Days Post Comirnaty Vaccine
Nomy Levin-Iaina[SUP] 1 2 [/SUP], Avital Angel-Korman[SUP] 3 1 [/SUP], Adi Leiba[SUP] 3 1 4 [/SUP], Esther Peres[SUP] 3 [/SUP], Gabriel Bryk[SUP] 5 [/SUP], Vladimir Rapoport[SUP] 3 [/SUP], Zeev Katzir[SUP] 3 1 [/SUP], Yoram Yagil[SUP] 1 4 2 [/SUP], Tal Brosh-Nissimov[SUP] 6 1 [/SUP]
Affiliations
- PMID: 35598056
Abstract
Background: The reduced immune response of maintenance hemodialysis patients to coronavirus disease 2019 (COVID-19) vaccines is a major concern.
Objectives: To analyze the late (6 months after full vaccination) antibody response and compare it to early post-vaccination titer.
Methods: We conducted a multicenter prospective study of 13 hemodialysis units in Israel.
Results: We demonstrated that the low titers observed among ESRD patients 2-3 months after vaccination with the Comirnaty vaccine (median 63.8 AU/ml) declined to critically lower values 6 months after full vaccination. (Mediananti S antibodies, 31 AU/ml). Seropositivity significantly declined among hemodialysis patients from 89% to 74% (P < 0.0001), although it did not significantly change among controls.
Conclusions: We recommend all patients on hemodialysis receive a booster COVID-19 vaccine 6 months after the second dose.